Skip to content
-
Subscribe to our newsletter & never miss our best posts. Subscribe Now!
Today's News. Tomorrow's Perspective. Today's News. Tomorrow's Perspective.

Deliver fast, factual, and easy-to-understand news covering global events, technology, business, science, AI, health, entertainment, and lifestyle.

Today's News. Tomorrow's Perspective. Today's News. Tomorrow's Perspective.

Deliver fast, factual, and easy-to-understand news covering global events, technology, business, science, AI, health, entertainment, and lifestyle.

  • Home
  • Breaking News
  • Business
  • Sports
  • Health
  • Politics
  • Technology & AI
  • World
  • Home
  • Breaking News
  • Business
  • Sports
  • Health
  • Politics
  • Technology & AI
  • World
Close

Search

Subscribe
Dropping GLP-1 coverage leaves workers 'terrified'
Health

Dropping GLP-1 coverage leaves workers ‘terrified’

Stephen Atcheler
By Stephen Atcheler
November 21, 2026 1 Min Read
Comments Off on Dropping GLP-1 coverage leaves workers ‘terrified’

A costly class of weight-loss drugs is colliding with employers’ balance sheets, and many workers are finding themselves stuck in the middle, NBC News reports. Shannon Pettypiece explains how companies that once embraced GLP-1 drugs like Wegovy and Zepbound are now reducing their coverage as healthcare costs rise. In a Business Group on Health survey, the share of large employers covering GLP-1 for weight loss fell from 72% in 2025 to 60% this year, with none of the 127 employers planning to add the benefit again. Big names cutting or reducing their coverage include Starbucks, UPS, PepsiCo, University of Louisville, Mass General Brigham and Comcast.

Executives argue that drugs are among the fastest-rising expenses and that cuts are needed to keep health plans affordable, while doctors and obesity advocates warn that the sudden end of coverage for what they view as chronic disease treatment creates a two-tiered system: people who can afford several hundred dollars a month in out-of-pocket expenses, and those who cannot. Patients describe resorting to tapering programs, increasing doses, or even stopping altogether, telling Pettypiece that they are “terrified” of what will happen to their health. For the real-world stories, hard numbers and employer rationales, read Pettypiece’s full article on NBC News.

Gn Health

Views: 6
Stephen Atcheler
Author

Stephen Atcheler

**Stephen** is a staff journalist at **DailyVoxa**, specializing in business, finance, technology, artificial intelligence, and global markets. He is committed to delivering timely, accurate, and insightful reporting that helps readers understand the forces shaping the global economy and the rapidly evolving digital landscape.Drawing on in-depth research and credible sources, Stephen covers breaking developments, industry trends, and emerging innovations with a focus on clarity, balance, and factual accuracy. His reporting is designed to provide readers with reliable information, practical context, and thoughtful analysis without sensationalism.As a member of the DailyVoxa editorial team, Stephen follows the publication's Editorial Policy, Fact-Checking Policy, Corrections Policy, and Ethics Policy. Every article is carefully reviewed to ensure it meets the highest standards of journalistic integrity, transparency, and editorial independence.

Follow Me
Other Articles
Congress finalizes bill to officially ban Chinese cars in the United States
Previous

Congress finalizes bill to officially ban Chinese cars in the United States

Mexican president spent 21 hours on bus to China and sat in middle seat
Next

Mexican president spent 21 hours on bus to China and sat in middle seat

Deliver fast, factual, and easy-to-understand news covering global events, technology, business, science, AI, health, entertainment, and lifestyle.
  • About Us
  • Accessibility Statement
  • Advertise With Us
  • AI Usage & Transparency Policy
  • Contact us
  • Cookie Policy
  • Corrections Policy
  • Meet Our Team
  • Privacy Policy
    • Disclaimer
    • DMCA & Copyright Policy
    • Editorial Policy
    • Ethics Policy
    • Fact-Checking Policy
  • Terms and Conditions
Copyright 2026 — Today's News. Tomorrow's Perspective.. All rights reserved.